Market Research Report
Global Myelofibrosis Therapeutics Market 2018-2022
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||773824|
|Published||Content info||106 Pages
Delivery time: 1-2 business days
|Global Myelofibrosis Therapeutics Market 2018-2022|
|Published: December 21, 2018||Content info: 106 Pages||
Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio's analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.
Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.
The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.
For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.
The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.